2018年重症医学回顾与展望
本文回顾2018年重症医学领域的重要进展与争议。国际指南修订脓毒症与脓毒性休克管理的「1小时集束化治疗」;食管测压监测跨肺压用于ARDS模型;新型抗生素、血管紧张素Ⅱ用于血管扩张性休克及肾脏替代治疗患者、院外心脏骤停高级气道管理及脓毒性休克细胞免疫治疗等试验取得成功。但ECMO治疗ARDS、早期拔管序贯无创通气、氟哌拉醇预防谵妄、ICU跨专业团队替代决策及泮托拉唑预防应激性溃疡等研究未达预期。反对指南制定、强制实施集束化策略、羟乙基淀粉溶液市场地位及脓毒性休克使用类固醇等声音与证据增强,凸显分歧与争议。
要点
- 国际指南修订脓毒症与脓毒性休克管理的「1小时集束化治疗」。
- 食管测压监测跨肺压用于急性呼吸窘迫综合征模型。
- 血管紧张素Ⅱ用于血管扩张性休克及肾脏替代治疗患者。
- ECMO治疗ARDS、早期拔管序贯无创通气、氟哌啶醇预防谵妄、泮托拉唑预防应激性溃疡等试验未获预期结果。
- 反对指南制定、强制集束化策略、羟乙基淀粉溶液市场地位及脓毒性休克使用类固醇的声量与证据增强。
研究设计与关键结果
- 2018年国际指南修订脓毒症与脓毒性休克管理的「1小时集束化治疗」。
- 食管测压监测跨肺压用于急性呼吸窘迫综合征模型。
- 新型抗生素、血管紧张素Ⅱ用于血管扩张性休克及肾脏替代治疗患者、院外心脏骤停高级气道管理及脓毒性休克细胞免疫治疗等试验取得成功。
- ECMO治疗ARDS、早期拔管序贯无创通气、氟哌啶醇预防谵妄、ICU跨专业团队替代决策及泮托拉唑预防应激性溃疡等研究未获预期结果。
- 反对指南制定、强制实施集束化策略、羟乙基淀粉溶液市场地位及脓毒性休克使用类固醇的声量与证据增强,凸显分歧与争议。
证据类型、等级与局限
- 综述
- 局限:原文未报告局限性
对床旁实践的改变
- 原文未据此给出推荐
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
In 2018, a bunch of considerable positive progresses have been presented, including a revised "hour-1 bundle" introduced by international guideline for management of sepsis and septic shock, trans-pulmonary pressure monitoring via esophageal manometry in acute respiratory distress syndrome (ARDS) models, successful trials for new antibiotics, angiotensin II in patients with vasodilatory shock and renal replacement therapy, advanced airway management in out-of-hospital cardiac arrest (OHCA) patients as well cellular immunotherapy for septic shock. But some of investigational trials did not yield expected results. For example, extracorporeal membrane oxygenation (ECMO) therapy for ARDS patients, the strategy of sequencing weaning with early extubation to noninvasive ventilation, prevention of delirium with haloperidol, surrogate decision supported by interprofessional intensive care unit (ICU) team and prophylaxis for gastrointestinal stress ulceration with pantoprazole in ICU. And more importantly, it has been obvious that the voices and evidences gathered by the opponents against guidelines development, compulsory polices of implementing bundled strategy, market position of hydroxyethyl-starch solutions (HES) and the usage of steroid in septic shock have been largely strengthen, highlighting a more divided and controversial situation.
参考来源
- Huang W, Qin Y. [Review and forecast of critical care medicine in 2018]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 30707863. doi:10.3760/cma.j.issn.2095-4352.2019.01.005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。